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Pharmacogenetics is hardly a new ﬁeld,
with early discoveries of genetic differ-
ences in drug-metabolizing enzymes dat-
ing back to the early 1960s. However, de-
spite the increasing knowledge base
regarding variation in drug response and
toxicityrelatedtopharmacogeneticfactors
and the simpliﬁcation and increasedavail-
ability of molecular technologies, there
have been major barriers to the introduc-
tion of genetic testing into routine clinical
practice [1]. Factors favoring uptake of a
genetic testintoclinicalpracticeareshown
in table 1. The lack of incorporation of
testing into practice has related primarily
to (1) the availability of laboratory mark-
ers that correctlyphenotypedrugresponse
or toxicity (e.g., drug levels for anticon-
vulsants or international normalized ratio
for warfarin), (2) the lack of standardized
clinical or laboratory guidelines or algo-
rithmsfortheinterpretationofgenetictest
results, and (3) the paucity of evidence-
based medicine showing that the pro-
spective use of pharmacogeneticscreening
positively impacts patient outcome.
Abacavir hypersensitivity reaction is a
potentiallylife-threateningdiseasethatoc-
curs in ∼5% of patients initiating therapy
with this drug. It sets itself apart from the
majority of other drug toxicities encoun-
tered in clinical practice—which tend to
be multifactorial in etiology, dose related,
and pharmacologically predictable—in
that its occurrence appears to be largely
unrelated to dose, and its clinical presen-
tation is more severe in cases of reexpo-
sure. Furthermore, clinical diagnosis of
this disease (which most commonly pres-
ents 9–11 days after initiation of therapy)
has been confounded by an overlap of
symptoms and signs with those of other
drug hypersensitivities, viral infections,
and immune restoration diseases. Al-
though the occurrence of abacavir hyper-
sensitivity reaction has been more com-
mon in Caucasian subjects (occurring in
8% of such subjects who initiate abacavir
therapy), other clinical factors have not
been useful in the prediction of this dis-
ease, and the risk of morbidity and even
mortality on rechallenge precludes future
use of abacavir in an individual who has
been labeled withabacavirhypersensitivity
syndrome.
A major breakthroughoccurredin2002
with the publication by 2 independent
groups of a strong association between a
speciﬁc HLA (HLA-B*5701) and abacavir
hypersensitivity reaction [2, 3]. In this is-
sue of Clinical Infectious Diseases, one of
these groups—from Perth, Western Aus-
tralia—describes their experience with the
implementation of prospective screening
for HLA-B*5701 in a single-center cohort
since January 2002, compared with their
experience in the prescreening era from
January 1998 through December2001[4].
Convincingly, this study has shown that,
of 148 patients found to be HLA-B*5701
negative and exposed to abacavir since
January 2002, only 6 patients (4%) had
abacavir discontinued within 6 weeks; all
6 of these patients had presentations clin-
ically inconsistent with abacavirhypersen-
sitivity reaction (nonspeciﬁc symptoms,
single-symptomdisease,orsymptomsthat
did not respond to abacavir dechallenge).
These patients were also found to have
negative results of patch testing,whichhas
emerged as a promising diagnostic tech-
nique for conﬁrmation of abacavir hy-
persensitivityreaction[5].Ofnote,among
151 patients exposed to abacavir, each of
the 3 patients who developed convincing
clinical evidence of abacavir hypersensi-
tivity reaction had been HLA-B*5701 pos-
itive on screening, with 2 of these 3 pa-
tients being inadvertently exposed to
abacavir because of a lack of review of
HLA results before abacavir prescription
and 1 of these 3 patients being exposed
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Table 1. Factors favoring implementation of a pharmaco-
genetic test into clinical practice.
Application of test improves clinical outcome
Ready availability and/or rapid low-cost test
High predictive value of test
Identiﬁcation of clinical parameters that determine usefulness
Ease of incorporation into routine management
Figure 1. The prevalence of HLA-B*5701 in different parts of the world. These carriage frequencies mirror the incidence of abacavir hypersensitivity
in exposed individuals. Adapted from [7].
on the basis of his own consent. All 3 of
these patients had strongly positive aba-
cavir patch test results. Overall,despitethe
prescription of abacavir for 3 patients
known to be HLA-B*5701 positive, this
group was able to show a statistically sig-
niﬁcant decrease in theincidenceof“true”
abacavir hypersensitivity reaction, from
8% in the era before genetic screening for
HLA-B*5701 to 2% after the implemen-
tation of genetic screening.
Thereareseveralimportantconclusions
and implications of this study that should
be highlighted. First, this is one of the ﬁrst
studies in which prospective implemen-
tation of a pharmacogenetic screeningtest
that requires a yes or no interpretationhas
been shown to convincingly reduce the
occurrence of a deﬁned toxicity. Perhaps
of even more interest, this study has
shown not only that implementation of
geneticscreeningwasassociatedwithasig-
niﬁcant reduction in the incidence of true
abacavir hypersensitivity but also that the
incidence of overall early abacavir discon-
tinuations decreased from 16.5% in the
prescreening era to 6% after screeningwas
implemented[4].Onemightinterpretthis
as implying that we have become better at
the clinical diagnosis of abacavir hyper-
sensitivity reaction over time; however,
other groups not using screening have, in
fact, seen an increase in early discontin-
uation of abacavir therapy since 2001 [6].
An alternate explanation is that genetic
screening provides additionalinformation
that allows clinical pharmacovigilence to
be applied more intelligently to an indi-
vidual patient population.
Where does this leave us in terms of the
application of genetic screening for HLA-
B*5701 to our own clinic populations in-
itiating abacavir therapy? First, there are
several practical issues with regard to
broad-based application of screening to
HIV clinic populations. Clearly, theutility,
cost-effectiveness, and generalizability of
genetic screening to a given clinic popu-
lation will depend on knowledge of the
prevalence of HLA-B*5701 in that popu-
lation, which has been shown to be closely
linked to the incidence of abacavir hyper-
sensitivity reaction in a given population.
In clinics serving a predominantly Cau-
casian population, the overall incidenceof
abacavir hypersensitivityis5%–8%,which
means that, from a feasibility and cost-
effectiveness standpoint,only∼14patients
would need to be screened to prevent 1
case of abacavir hypersensitivity reaction.
However, this ratio would be much less
cost-effective in certain Asian and African
black populations, for whom the preva-
lence of HLA-B*5701 is !1% (ﬁgure 1).
The wide range of frequencies of abacavir
hypersensitivity reaction describedinclin-
ical trials (0%–14%) is at least in part at-
tributable to ethnic or racial differences in
enrollees in these studies. Regardless, the
clinical implications of HLA-B*5701 pos-
itivity appear to be the same, and we as-
sume that an HLA-B*5701–positive Afri-
can black subject is just as likely to
experience abacavir hypersensitivity reac-
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tion as an HLA-B*5701–positive Cauca-
sian subject. In addition, data from patch
testing studies, which to date have shown
100% correlation between positive patch
test results and HLA-B*5701 positivity
(and which have identiﬁed no other ge-
netic markers independently associated
with abacavir hypersensitivity reaction),
have been reassuring [8, 9].
At the end of the day, we have to be
clear about both what we can and what
we cannot currently accomplish with
HLA-B*5701 screening for abacavir hy-
persensitivity reaction. The data from
Western Australia [4] reassures us that ge-
netic screening can prevent true abacavir
hypersensitivityand,intriguingly,mayalso
lower the rate of false-positive diagnosis
of abacavir hypersensitivity syndrome.
Screening, therefore, shows promise to be
cost-effective, both by lowering the mor-
bidity associated with truehypersensitivity
reactions and by reducing inappropriate
early discontinuation of therapy. Impor-
tantly, a point that is often overlooked is
that screening should actuallysigniﬁcantly
increase the safety of abacavir use by pro-
moting proactive avoidance of abacavir
use in the HLA-B*5701–positive popula-
tion, who would be at risk for death as
the result of inadvertent rechallenge with
abacavir.
Genetic screening for abacavir hyper-
sensitivity reaction also warrants a few
words of caution. Screening should pro-
mote a more intelligent pharmacovigil-
ence, but it should in no way be used as
a substitute for clinical judgment or phar-
macovigilence. A large, randomized, con-
trolled trial is planned that will enrollsub-
jects from sites in Europe and Australia;
this trial will provide more-deﬁnitive in-
formation on the utility and generaliza-
bility of HLA-B*5701 screening in diverse
populations. At this time, HLA-B*5701
screening is best positioned as a screening
test for abacavir-naive populations and
should not be used as a rationale for re-
challenge in abacavir-exposed individuals.
Because high-resolution HLA typing is
costly, is performed in specialized im-
munology and transplant laboratories,
and has long turnaround times, more-
rapid and cheaper validated molecular
tests, such as the recently published HLA-
B57 sequence-speciﬁc ampliﬁcation and
ﬂow cytometric techniques, will be wel-
comed [10, 11]. Rauch et al. [4], in their
description of 2 HLA-B*5701–positivepa-
tients who were inadvertently exposed to
abacavir despite positive screening results,
emphasize an important point: genetic
screening will simply not work unless the
test results are acted upon! Ensuring the
reliable and timely transmission of infor-
mation from laboratory to clinician will
be vital to the safety and success of such
genetic screening programs.
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